Escitalopram & Aripiprazole for psychiatric disorders in youth

December 2020 **Dr. Ladan Adibeshgh** pharmacist



Pharmacotherapy of psychiatric illnesses in children and adolescents has grown significantly over the last few decades.

However, the body of research examining pharmacological treatments for psychiatric illnesses is much smaller in children and adolescents than it is in adults.

As most treatments for psychiatric disorders are more effective if started early in the course of illness, treatment options for youth are especially important in order to ensure better treatment outcomes.

Childhood depression has been shown to lead to an increased risk of poor academic performance, impaired social functioning, suicidal behavior, homicidal ideation, and alcohol/substance abuse.





Antidepressants

>Antidepressants are used to treat depression and anxiety disorders in children.

SSRIs are the most commonly used antidepressants in pediatric populations due to their demonstrated <u>efficacy</u>, low side effect profile, and good tolerability.







Escitalopram (Escitover®)

Antidepressant, Selective Serotonin Reuptake Inhibitor





- The S(+)-enantiomer of citalopram
- Inhibitor of serotonin reuptake with no effects on norepinephrine or dopamine
- In addition to SERT inhibition, citalopram is a mild antagonist at histamine 1 receptors. Escitalopram is also a SERT inhibitor, but doesn't block H1 receptors.






Escitalopram & Aripiprazole for psychiatric disorders in youth I page 5

FDA-Approved Indications

Indication	Citalopram	Escitalopram
Major depressive disorder (unipolar)	V	V
Generalized anxiety disorder		V
Depression (Children and Adolescents ≥12 years)		V

Figure 1. FDA-Approved Pediatric Age Ranges and Indications for Antidepressant Medications



Escitalopram & Aripiprazole for psychiatric disorders in youth I page 6



Depression

Children and Adolescents ≥12 years

Initial: 10 mg once daily; may be increased to 20 mg/day after at least 3 weeks

Note: Some experts suggest lower starting doses of 5 mg/day and lower titration increments of 5 mg in patients sensitive to adverse effects, particularly in patients with anxiety who are generally more sensitive to overstimulation effects (eg, anxiety, insomnia) with antidepressants (Hirsch 2018c; WFSBP [Bandelow 2012]).





Most common side effects:

CNS: Headache, insomnia, drowsiness

↔GI: Nausea, diarrhea

*****Genitourinary: Ejaculatory disorder

They're usually mild and go away after a couple of weeks.



Escitalopram & Aripiprazole for psychiatric disorders in youth I page 8

Primary Care Clinicians Can Effectively Treat Depression in Children and Adolescents

Original Article: Depression in Children and Adolescents: Evaluation and Treatment

Issue Date: November 15, 2019

See additional reader comments at: https://www.aafp.org/afp/ 2019/1115/p609.html

 Evidence supports the use of fluoxetine and escitalopram as first-line agents for unipolar depression in children and adolescents without complex medical or psychiatric histories.

Selected Medications for the Treatment of Adolescent Mood Disorders

Medication*	Starting dosage (mg per day)	Dose adjust- ments† (mg per dose)	Therapeutic range (mg)	Maximum dosage (mg per day)
Selective serotonin reuptake inhibitors				
Citalopram (Celexa)	10	5 to 10	20 to 40	40
Escitalopram (Lexapro)	5 to 10	5	10 to 20	20
Fluoxetine (Prozac)	10	10 to 20	20 to 40	60 to 80
Sertraline (Zoloft)	25 to 50	25 to 50	50 to 200	200

Medication	Sedation	Agitation/Insomnia
Selective Serotoni	n Reuptake Inhib	itors
Fluoxetine	+	+ + + +
Sertraline	+	+ + +
Paroxetine	+ + +	++
Citalonnam	+ +	++
Citalopram	1.1	



Escitalopram & Aripiprazole for psychiatric disorders in youth l page 10

	Reuptake An	Reuptake Antagonism			Orthostatic		Conduction	
	Norepinephrine	Serotonin	Anticholinergic Effects	Sedation Hypotensic		Seizures ^a	Abnormalities ^a	
Selective Serotonin F	Reuptake Inhibitors (SSRIs)							
Citalopram	0	++++	0	+	0	++	++	
Escitalopram	0	++++	0	0	0	0	0	
Fluoxetine	0	+++	0	0	0	++	0	
Fluvoxamine	0	++++	0	+	0	++	0	
Paroxetine	0	++++	+	+	0	++	0	
Sertraline	0	++++	0	0	0	++	0	



Escitalopram & Aripiprazole for psychiatric disorders in youth l page 11

Guideline Recommendations

♦ NICE

- Compared to the 2010 guideline, the 2018 guideline included a new section on Escitalopram specifically.
- > More effective than citalopram and at least as effective as other SSRIs
- Better tolerability, except as compared to sertraline

* CANMAT

- Escitalopram as a "first line" treatment, along with all others
- Escitalopram, mirtazapine, sertraline, and venlafaxine: as "some antidepressants have modest superiority for treatment response, particularly."
- "Minimal or low potential" for drug-drug interactions


*****APA

- Slight superiority of Escitalopram over other SSRIs and venlafaxine
- > Favorable drug-drug interaction profile over that fluoxetine, fluvoxamine, and paroxetine

♦ RANZP

Reasonable efficacy and tolerability profile









Easy to be administered, safe in overdose







Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis


Andrea Cipriani, Toshi A Furukawa*, Georgia Salanti*, Anna Chaimani, Lauren Z Atkinson, Yusuke Ogawa, Stefan Leucht, Henricus G Ruhe, Erick H Turner, Julian P T Higgins, Matthias Egger, Nozomi Takeshima, Yu Hayasaka, Hissei Imai, Kiyomi Shinohara, Aran Tajika, John P A Ioannidis, John R Geddes





Escitalopram & Aripiprazole for psychiatric disorders in youth l page 15

Efficacy (A) and acceptability (B)



0.88 (0.80-0.96) 0.90(0.80-1.02)0.93 (0.72-1.19) 0.94(0.80-1.09)0.95 (0.83-1.08) 0.95(0.87 - 1.03)0.95 (0.73-1.26) 0.96 (0.85-1.08) 0.96 (0.81-1.14) 0.99 (0.85-1.15) 1.01 (0.86-1.19) 1.04 (0.93-1.15) 1.08 (0.88-1.33) 1.09 (0.96-1.23) 1.10(0.91-1.33)1.14(0.88 - 1.47)1.15(0.93 - 1.42)1.16(0.96 - 1.40)1.19 (0.93-1.53) 1.30 (1.01-1.68)



OR (95% Crl)

0.84 (0.72-0.97)

International Journal of Neuropsychopharmacology (2011), **14**, 261–268. © CINP 2010 doi:10.1017/S146114571000115X

Efficacy of escitalopram compared to citalopram: a meta-analysis

Stuart Montgomery¹, Thomas Hansen² and Siegfried Kasper³


¹ University of London, UK

² H. Lundbeck A/S, Denmark


³ Department of Psychiatry and Psychotherapy, Medical University Vienna, Austria



Escitalopram & Aripiprazole for psychiatric disorders in youth l page 17



Escitalopram & Aripiprazole for psychiatric disorders in youth I page 18



The week at which the of mean scores escitalopram-treated or citalopram-treated patients on various rating scales were first statistically significantly different from placebotreated patients is shown as a clock display in which the size of the white wedge corresponds to the time required achieve separation to from placebo.



Children and adolescents

JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY Volume XX, Number XX, 2018 © Mary Ann Liebert, Inc. Pp. 1–8 DOI: 10.1089/cap.2017.0174

Update on Randomized Placebo-Controlled Trials in the Past Decade for Treatment of Major Depressive Disorder in Child and Adolescent Patients: A Systematic Review

Martha J. Ignaszewski, MD,^{1,2} and Bruce Waslick, MD,^{3,4}

Escitalopram & Aripiprazole for psychiatric disorders in youth I page 20



The totality of available evidence support the use of fluoxetine and Escitalopram as first-line medication treatment for youth with depressive disorders and demonstrated effect to prevent relapse.

There were no statistically significant suicidal signal increases in acute Escitalopram treatment compared with placebo.

Discontinuation rates of Escitalopram were low generally due to adverse effects compared with placebo.



Escitalopram & Aripiprazole for psychiatric disorders in youth l page 21

Anxiety disorders or anxiety symptoms are frequent comorbid conditions among children and adolescents with depressive disorders

An Open-Label Trial of Escitalopram in Children and Adolescents with Social Anxiety Disorder

Luciano Isolan M.D., Gabriel Pheula M.D., Giovanni Abrahão Salum, Jr., Sylvia Oswald, Ph.D., Luis Augusto Rohde, M.D., Ph.D., and Gisele Gus Manfro, M.D., Ph.D.

JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY Volume 17, Number 6, 2007 © Mary Ann Liebert, Inc. Pp. 751–759 DOI: 10.1089/cap.2007.0007

Escitalopram & Aripiprazole for psychiatric disorders in youth l page 22



All symptomatic and quality of life measures showed <u>improvements</u> from baseline to week 12.

Escitalopram was generally well-tolerated.

♣All <u>adverse events</u> ranged from mild to moderate in intensity.

There were no clinically significant changes in vital signs or weight.

These results suggest that escitalopram may be an <u>effective</u> and <u>safe</u> treatment for <u>pediatric SAD</u>.



Pharmacotherapy for treatment-respondent vs. refractory obsessive-compulsive disorder in children and adults: strategies, meta-analyses and clinical guidelines

Mehdi Sayyah, Fakher Rahim

- Obsessive—compulsive disorder (OCD) is a common mental health disorder that occurs at all ages, but more commonly in younger people.
- In children with OCD the greatest incremental treatment gains occur early in treatment with SSRIs.
- In treatment-resistant OCD augmentation of SRIs can be regarded as an evidencebased measure in pharmacological therapy.
- Antipsychotics combination/augmentation of SSRIs should be used in comorbid psychosis, a frequent comorbidity in OCD



Pharmacotherapy for treatment-respondent vs. refractory obsessive-compulsive disorder in children 45




Figure 1. Conventional treatment options usually considered in Obsessive-Compulsive Disorder (OCD)





Fig. 2. Pharmacological management of treatment-resistant OCD




Improved side-effect profile





Antipsychotic

- There is less evidence for the use of first-generation antipsychotics (FGA), such as haloperidol, molindone, and pimozide, in the pediatric population.
- <u>Compared to</u> the second generation antipsychotics (SGA), including risperidone, Aripiprazole, quetiapine, olanzapine, and others.





Escitalopram & Aripiprazole for psychiatric disorders in youth l page 28





Aripiprazole (Arizover®)

Second Generation (Atypical) Antipsychotic

Escitalopram & Aripiprazole for psychiatric disorders in youth I page 29



Madiaatian	FDA-approved	Age range,	Recommended dos	
Medication	indication	years	range, mg	
Risperidone	Schizophrenia	13–17	1-6	
	BD (mixed/manic episode)	10–17	1-6	
	Irritability, associated with ASD	5-18	0.5–3	
Aripiprazole	Schizophrenia	13-17	10-30	
	BD (mixed/manic episode)	10–17	10-30	
	Irritability, associated with ASD	6-17	5-15	
	Tourette's disorder	6-18	<50 kg - 5 to 10 $\ge 50 \text{ kg} - 10 \text{ to } 20$	
Olanzapine	Schizophrenia	13–17	10	
	BD (mixed/manic episode)	13–17	10	
Asenapine	BD (mixed/manic episode)	10–17	2.5–10 twice daily	
Quetiapine	Schizophrenia	13–17	400-800	
	BD (mixed/manic episode)	10–17	400-600	
Lurasidone	Schizophrenia	13–17	40-80	
	BD (depressive episode)	10–17	20-80	
Paliperidone	Schizophrenia	12–17	<51 kg - 3 to 6 $\ge 51 \text{ kg} - 3 \text{ to } 12$	
Olanzapine/fluoxetine combination	BD (depressive episode)	10–17	3/25-12/50	

Country	Year of first approval	SCZ	Bipolar disorder	Behavior impairments associated with autism or intellectual disability	Tourette's syndrome
United States	2007	>13 Years	>10 Years	>6 Years	>6 Years
UE	2012		>13 Years		
Canada	2013	>15 Years	>13 Years		
France	2009 SCZ and 2016 BP	>15 Years	>13 Years		
Suisse	2018	>13 Years	>13 Years		
Indonesia	2018	Children	Children		
Philippines	2018				>6 Years

TABLE 1. ARIPIPRAZOLE IN CHILDREN AND ADOLESCENTS: WORLDWIDE AGENCIES' AUTHORIZATION (UNTIL APRIL 2019)

Modified from Perraudin et al. (2018).

BP, bipolar disorder; SCZ, schizophrenia.

- Aripiprazole is one of the most widely prescribed atypical antipsychotics, due to a:
- ✓ Well-established efficacy profile
- ✓ Safety profile
- Adverse effects are more important in children and adolescents, (weight gain, drowsiness, extrapyramidal effects, and metabolic effects)





******Autistic disorder ; 6 to 17 Years*

Initial: 2 mg daily, for 7 days, followed by 5 mg daily Dose increase: 5 mg/day increments every ≥7 days Maximum: 15 mg/day

*****Bipolar I disorder, Acute treatment of manic or mixed episodes; 10 to 17 years

- Manic and mixed episodes associated with Bipolar I Disorder
- > Monotherapy
- Adjunctive to lithium or valproate
- Maintenance treatment of Bipolar I Disorder
- Agitation associated with bipolar mania





☆*Tourette's syndrome; ≥8 years*

Less than 50 kg

Initial: 2 mg/d for 2 days, then increase to 5 mg/day Maximum dose: 10 mg/d

50 kg or Greater

Initial: 2 mg/d for 2 days, then increase to 5 mg/d for 5 days, and then to target dose of 10 mg/d on day 8 Maximum dose: 20 mg/d

Schizophrenia: 13 to 17 Years

Initial: 2 mg/d , then increase to 5 mg after 2 days and then to 10 mg after an additional 2 days

Maintenance dosage: 10 mg/d


subsequent dose increases may be made in 5 mg increments up to a maximum daily dose of 30 mg/day



Article

(Am J Psychiatry 2008; 165:1432–1441)

A Multiple-Center, Randomized, Double-Blind, Placebo-Controlled Study of Oral Aripiprazole for Treatment of Adolescents With Schizophrenia



Conclusion: Both 10- and 30-mg/day doses of aripiprazole were superior to placebo in the acute treatment of adolescents with schizophrenia. Aripiprazole was generally well tolerated.

Adverse events:

Aripiprazole treatment was generally well tolerated and not dose limiting.



Escitalopram & Aripiprazole for psychiatric disorders in youth I page 34

Wider spectrum of psychiatric disorders in children and adolescents

Eur Child Adolesc Psychiatry (2012) 21:361–368 DOI 10.1007/s00787-012-0270-0

25 March 2012

REVIEW

Efficacy and safety of aripiprazole in child and adolescent patients

Eiji Kirino

- Body weight and metabolic parameters
- Serum prolactin significantly lower after APZ administration than at baseline: growth and sexual maturation
- Cardiovascular problem: no changes evident in blood pressure, heart rates, ECG, or the QTc interval in trials
- Low sedation: learning ability
- Few side effects (such as EPS, hyperprolactinemia, weight gain, metabolic disorders, and sedation)



- Aripiprazole has demonstrated a relatively favorable tolerability profile.
- ➢Lower potential for weight gain or metabolic changes
- Lower liability for extrapyramidal symptoms (compared to many FGA)
- Lower Sedation (compared to more other antipsychotics)
- Lower hyperprolactinemia (compared to risperidone, paliperidone or amisulpride)
- ≻Lower QTc prolongation (compared to the older, FGA)



In a comparison study, aripiprazole and risperidone similarly reduced irritability scores in children with ASD, but aripiprazole showed effects more quickly

A Head-to-Head Comparison of aripiprazole and risperidone for safety and treating autistic disorders, a randomized double blind clinical trial

Running title: comparing aripiprazole and risperidone for treating autism





OCD

Aripiprazole Treatment for Obsessive Compulsive Disorder in 2 Young Subjects Who Could Not Tolerate Selective Serotonin Reuptake Inhibitors (SSRIs)

S SRIs are the mainstay pharmacological treatment of obsessive compulsive disorder (OCD) in young subjects.^{1–3} Despite that they are generally safe and well tolerated in young subjects with OCD, some subjects may develop adverse effects that may limit or discourage the use of SSRIs.^{3–7} Here, we present 2 pediatric cases who could not tolerate fluoxetine or sertraline for the treatment of OCD. Fluoxetine or sertraline were discontinued in these subjects, and they were treated successfully without any significant adverse effects with using low dose of aripiprazole.

Aripiprazole Monotherapy Was Effective in Treating Obsessive-Compulsive Disorder in a Preschool Boy

A ripiprazole augmentation has been reported effective in the treatment of obsessive-compulsive disorder (OCD) in young and adult subjects.^{1–3} Here, a case of a pre-school boy with multiple psychiatric diagnoses whose primary complaint was distressing symptoms of OCD is reported. He developed manic reaction with escitalopram-risperidone combination treatment. Then he was switched to aripiprazole monotherapy for his OCD and other behavioral symptoms. Clinical picture of the subject and successful treatment with aripiprazole monotherapy are discussed in this very young subject.



Aripiprazole in the Treatment of Pediatric Bipolar Disorder: <u>A Systematic Chart Review</u>


By Joseph Biederman, MD, Mary Ann McDonnell, APRN, BC, Janet Wozniak, MD, Thomas Spencer, MD, Megan Aleardi, BA, Richard Falzone, MD, and Eric Mick, ScD


FOCUS POINTS

- Bipolar and bipolar spectrum disorder are common in children.
- Atypical neuroleptics have been found to be efficacious in the management of youth with bipolar and bipolar spectrum disorder.
- Aripiprazole appears to be a promising and well-tolerated agent in the treatment of children and adolescents with bipolar disorder.



Escitalopram & Aripiprazole for psychiatric disorders in youth l page 39







Double-Blind, Randomized, Placebo-Controlled Long-Term Maintenance Study of Aripiprazole in Children With Bipolar Disorder

Robert L. Findling, MD, MBA; Eric A. Youngstrom, PhD; Nora K. McNamara, MD; Robert J. Stansbrey, MD; Jaime L. Wynbrandt, MA; Clara Adegbite, BA; Brieana M. Rowles, MA; Christine A. Demeter, MA; Thomas W. Frazier, PhD; and Joseph R. Calabrese, MD

> A growing body of research has documented the validity, chronicity, and seriousness of a bipolar diagnosis in patients under 10 years of age.^{4–18} Owing to the severity and persistence of bipolarity in this patient group, safe and effective long-term intervention strategies are needed. This study tested the maintenance efficacy of aripiprazole in children with a bipolar disorder.



Escitalopram & Aripiprazole for psychiatric disorders in youth l page 41

٩.

Antipsychotics cause hyperprolactinemia through their primary mechanism of dopamine (D2) receptor antagonism.


Open access	Systematic review
General Psychiatry	Adjunctive aripiprazole for antipsychotic-related hyperprolactinaemia in patients with first-episode schizophrenia: a meta- analysis

This meta-analysis of RCTs showed that adjunctive aripiprazole appears to be associated with reduced hyperprolactinemia induced by AP and improved prolactin-related symptoms in first-episode schizophrenia.

Zheng W, Cai DB, Yang XH, Ungvari GS, Ng CH, Shi ZM, Hu ML, Ning YP, Xiang Escitalopram & Aripiprazole for VST/cAdjunctive and piprazole for antipsychotic-related hyperprolactinaemia in patients with first-episode schizophrenia: a meta-analysis. General Psychiatry. 2019;32(5). Together for a healthy future



Thanks for your attention



www.actoverco.com

